目錄:MedChemExpress LLC>>抗體抑制劑>> Bevacizumab (PBS) | MCE
CAS | 216974-75-3 | 純度 | 98.94% |
---|---|---|---|
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-P9906A | 應用領域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,,我們不為任何個人用途提供產(chǎn)品和服務。
產(chǎn)品活性:Bevacizumab 是一種人源化的 IgG1 單克隆抗體,高親和力且特異性地與所有 VEGF-A 結(jié)合,。
研究領域:Protein Tyrosine Kinase/RTK
作用靶點:VEGFR
In Vitro: Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
In Vivo: It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p?0.01).
相關(guān)產(chǎn)品:5α-Hydroxycostic acid | GW806742X hydrochloride | Sorafenib-d4 | BMS-690514 | VEGFR-2-IN-6 | PROTAC VEGFR-2 degrader-1 | Multi-kinase-IN-2 | Sorafenib Tosylate | K00546 | c-Met-IN-11 | VEGFR-2-IN-29 | Threo-Chloramphenicol-d6 | Foretinib | ZM323881 hydrochloride | ODM-203 | Taurocholic acid sodium | VEGFR-2/DHFR-IN-2 | ENMD-2076 Tartrate | Albendazole | SU5408 | R1530 | AZD2932 | Toceranib phosphate | EGFR-IN-57 | Bevasiranib | Ponatinib hydrochloride | VEGFR-2-IN-28 | Famitinib malate | AhR modulator-1 | Hypothemycin
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑,、激動劑涉及各熱門信號通路及疾病領;
• 產(chǎn)品種類涵蓋各種重組蛋白,,多肽,,常用試劑盒 ,更有 PROTAC,、ADC 等特色產(chǎn)品,,廣泛應用于新藥研發(fā)、生命科學等科研項目,;
• 提供虛擬篩選,,離子通道篩選,代謝組學分析檢測分析,,藥物篩選等專業(yè)技術(shù)服務,;
• 設有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系,;
• 提供 LC/MS,、NMR、HPLC,、手性分析,、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度,、高品質(zhì),;
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果,;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作,。